Emerging targeted combinations in the management of breast cancer

References

• SchechterALSternDFVaidyanathanLThe neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigenNature198431259945135166095109
   PubMed Web of Science ®Google Scholar
• SlamonDGodolphinWJonesLStudies of the HER-2/neu proto-oncogene in human breast and ovarian cancerScience198924449057077122470152
   PubMed Web of Science ®Google Scholar
• RossJSSlodkowskaEASymmansWFPusztaiLRavdinPMHortobagyiGNThe HER-2 receptor and breast cancer: ten years of targeted anti–HER-2 therapy and personalized medicineThe Oncologist200914432036819346299
   PubMed Web of Science ®Google Scholar
• HudisCATrastuzumab – mechanism of action and use in clinical practiceN Engl J Med20073571395117611206
   PubMed Web of Science ®Google Scholar
• PerezEARomondEHSumanVJUpdated results of the combined analysis of NCCTG N9831 and NSABP B-31 adjuvant chemotherapy with/without trastuzumab in patients with HER2-positive breast cancerPaper presented at: ASCO Annual Meeting Proceedings Part I2007San Francisco
   Google Scholar
• SmithIProcterMGelberRD2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trialLancet20073699555293617208639
   PubMed Web of Science ®Google Scholar
• SlamonDEiermannWRobertNAdjuvant trastuzumab in HER2-positive breast cancerN Engl J Med2011365141273128321991949
   PubMed Web of Science ®Google Scholar
• AgusDBGordonMSTaylorCPhase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancerJ Clin Oncol200523112534254315699478
   PubMed Web of Science ®Google Scholar
• ChenXYeungTKWangZEnhanced drug resistance in cells coexpressing ErbB2 with EGF receptor or ErbB3Biochem Biophys Res Commun2000277375776311062025
   PubMed Web of Science ®Google Scholar
• GianniLLladóABianchiGOpen-label, Phase II, multicenter, randomized study of the efficacy and safety of two dose levels of pertuzumab, a human epidermal growth factor receptor 2 dimerization inhibitor, in patients with human epidermal growth factor receptor 2–negative metastatic breast cancerJ Clin Oncol20102871131113720124183
   PubMed Web of Science ®Google Scholar
• BaselgaJGelmonKAVermaSPhase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2–positive metastatic breast cancer that progressed during prior trastuzumab therapyJ Clin Oncol20102871138114420124182
   PubMed Web of Science ®Google Scholar
• BaselgaJCortésJKimS-BPertuzumab plus trastuzumab plus docetaxel for metastatic breast cancerN Engl J Med2012366210911922149875
   PubMed Web of Science ®Google Scholar
• SwainSMKimSBCortesJConfirmatory overall survival (OS) analysis of CLEOPATRA: a randomized, double-blind, placebo-controlled Phase III study with pertuzumab (P), trastuzumab (T), and docetaxel (D) in patients (pts) with HER2-positive first-line (1L) metastatic breast cancer (MBC)Cancer Research20127224 Suppl 3 abstract P5-18-26
   Google Scholar
• Lewis PhillipsGDLiGDuggerDLTargeting HER2-positive breast cancer with trastuzumab-DM1, an antibody–cytotoxic drug conjugateCancer Research200868229280929019010901
   PubMed Web of Science ®Google Scholar
• KropIEBeeramMModiSPhase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancerJ Clin Oncol201028162698270420421541
   PubMed Web of Science ®Google Scholar
• KropIELoRussoPMillerKDA Phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabineJ Clin Oncol201230263234324122649126
   PubMed Web of Science ®Google Scholar
• VermaSMilesDGianniLTrastuzumab emtansine for HER2-positive advanced breast cancerN Engl J Med2012367191783179123020162
   PubMed Web of Science ®Google Scholar
• DiérasVHarbeckNBuddGTTrastuzumab emtansine in HER2-positive metastatic breast cancer: pooled safety analysis from seven studiesCancer Research20127224 Suppl 3P5-18-06
   Web of Science ®Google Scholar
• EllisPBarriosCImYPatreMBranleFPerezEMARIANNE: A phase III, randomized study of trastuzumab-DM1 (T-DM1) with or without pertuzumab (P) compared with trastuzumab (H) plus taxane for first-line treatment of HER2-positive, progressive, or recurrent locally advanced or metastatic breast cancer (MBC)J Clin Oncol201129Suppl abstr TPS102
   Google Scholar
• AlvarezRHValeroVHortobagyiGNEmerging targeted therapies for breast cancerJ Clin Oncol201028203366337920530283
   PubMed Web of Science ®Google Scholar
• BaselgaJAlbanellJRuizAPhase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancerJ Clin Oncol200523235323533315939921
   PubMed Web of Science ®Google Scholar
• RobertsonJGutteridgeECheungKOwersRGefitinib (ZD1839) is active in acquired tamoxifen (TAM)-resistant oestrogen receptor (ER)-positive and ER-negative breast cancer: results from a phase II studyProc Am Soc Clin Oncol200322 abstr 23
   Google Scholar
• AlbainKElledgeRGradisharWJNataleRBOpen-label, phase II, multicenter trial of ZD 1839 (‘Iressa’) in patients with advanced breast cancerBreast Cancer Research And Treatment200276(S33)Suppl 1 abstr 20
   Google Scholar
• von MinckwitzGJonatWFaschingPA multicentre phase II study on gefitinib in taxane- and anthracycline-pretreated metastatic breast cancerBreast Cancer Res Treat200589216517215692759
   PubMed Web of Science ®Google Scholar
• CiardielloFTroianiTCaputoFPhase II trial of gefitinib combined with docetaxel as first-line therapy in patients with metastatic breast cancerBr J Cancer200694111604160916685276
   PubMed Web of Science ®Google Scholar
• EngebraatenOEdvardsenHLøkkevikEGefitinib in combination with weekly docetaxel in patients with metastatic breast cancer caused unexpected toxicity: results from a randomized Phase II clinical trialISRN Oncology201220128
   Google Scholar
• SmithIEWalshGSkeneAA Phase II placebo-controlled trial of neoadjuvant anastrozole alone or with gefitinib in early breast cancerJ Clin Oncol200725253816382217679728
   PubMed Web of Science ®Google Scholar
• CarlsonRWO’NeillAVidaurreTGomezHLBadveSRandomized phase II trial of gefitinib plus anastrozole or fulvestrant in postmenopausal, metastatic breast cancerJ Clin Oncol20092715S1013
   Google Scholar
• TwelvesCTrigoJMJonesRErlotinib in combination with capecitabine and docetaxel in patients with metastatic breast cancer: a dose-escalation studyEur J Cancer200844341942618249110
   PubMed Web of Science ®Google Scholar
• DicklerMNRugoHSEberleCAA phase ii trial of erlotinib in combination with bevacizumab in patients with metastatic breast cancerClin Cancer Res200814237878788319047117
   PubMed Web of Science ®Google Scholar
• KaurHSilvermanPSinghDCooperBWFuPKrishnamurthiSToxicity and outcome data in a phase II study of weekly docetaxel in combination with erlotinib in recurrent and/or metastatic breast cancer (MBC)J Clin Oncol20062418S10623
   Google Scholar
• MontagnaECancelloGBagnardiVMetronomic chemotherapy combined with bevacizumab and erlotinib in patients with metastatic HER2-negative breast cancer: clinical and biological activityClin Breast Cancer201212320721422520733
   PubMed Web of Science ®Google Scholar
• GrahamDLHillmanDWHobdayTJN0234: Phase II study of erlotinib (OSI-774) plus gemcitabine as first-or second-line therapy for metastatic breast cancer (MBC)J Clin Oncol20052316S64415659512
   PubMed Web of Science ®Google Scholar
• HobdayTJStellaPJFitchTRN0436: a phase II trial of irinotecan plus cetuximab in patients with metastatic breast cancer and prior anthracycline and/or taxane-containing therapyJ Clin Oncol200826Suppl abstr 1081
   Google Scholar
• CareyLARugoHSMarcomPKTBCRC 001: randomized phase ii study of cetuximab in combination with carboplatin in Stage IV triple-negative breast cancerJ Clin Oncol201230212615262322665533
   PubMed Web of Science ®Google Scholar
• GeyerCEForsterJLindquistDLapatinib plus Capecitabine for HER2-Positive Advanced Breast CancerNew England Journal of Medicine2006355262733274317192538
   PubMed Web of Science ®Google Scholar
• BaselgaJBradburyIEidtmannHLapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trialThe Lancet3799816633640
   Web of Science ®Google Scholar
• GelmonKABoyleFKaufmanBOpen-label phase III randomized controlled trial comparing taxane-based chemotherapy (Tax) with lapatinib (L) or trastuzumab (T) as first-line therapy for women with HER2+ metastatic breast cancer: Interim analysis (IA) of NCIC CTG MA.31/GSK EGF 108919J Clin Oncol201230Suppl 15 abstract LBA671
   Google Scholar
• CameronDCaseyMPressMA phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res TreatDec20081123533543
   Google Scholar
• LinNUDiérasVPaulDMulticenter Phase II Study of Lapatinib in Patients with Brain Metastases from HER2-Positive Breast Cancer. Clinical Cancer ResearchFebruary 15200915414521459
   Google Scholar
• PivotXSemiglazovVŻurawskiBCEREBEL (EGF111438): An open label randomized phase III study comparing the incidence of CNS metastases in patients (pts) with HER2+ Metastatic Breast Cancer (MBC), treated with Lapatinib plus Capecitabine (LC) versus Trastu-zumab plus Capecitabine (TC)Annals of Oncology201223Suppl 9 Abstract LBA11
   Google Scholar
• BursteinHJSunYDirixLYNeratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancerJ Clin Oncol20102881301130720142587
   PubMed Web of Science ®Google Scholar
• ShawRJCantleyLCRas, PI(3)K and mTOR signalling controls tumour cell growthNature2006441709242443016724053
   PubMed Web of Science ®Google Scholar
• JiangBHLiuLZRole of mTOR in anticancer drug resistance: perspectives for improved drug treatmentDrug Resistance Updates: Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy2008113637618440854
   PubMed Web of Science ®Google Scholar
• BachelotTBourgierCCropetCRandomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor–positive, human epidermal growth factor receptor 2–negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO StudyJ Clin Oncol201230222718272422565002
   PubMed Web of Science ®Google Scholar
• BaselgaJSemiglazovVvan DamPPhase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor–positive breast cancerJ Clin Oncol200927162630263719380449
   PubMed Web of Science ®Google Scholar
• BaselgaJCamponeMPiccartMEverolimus in postmenopausal hormone-receptor–positive advanced breast cancerN Engl J Med2012366652052922149876
   PubMed Web of Science ®Google Scholar
• Piccart-GebhartMJNoguchiSPritchardKIEverolimus for postmenopausal women with advanced breast cancer: Updated results of the BOLERO-2 phase III trialJ Clin Oncol201230Suppl abstr 559
   Google Scholar
• WolffACLazarAABondarenkoIRandomized phase III placebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancerJ Clin Oncol201331219520223233719
   PubMed Web of Science ®Google Scholar
• BaselgaJTargeting the phosphoinositide-3 (PI3) kinase pathway in breast cancerOncologist201116Suppl 1121921278436
   PubMed Web of Science ®Google Scholar
• Stemke-HaleKGonzalez-AnguloAMLluchAAn integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancerCancer Research200868156084609118676830
   PubMed Web of Science ®Google Scholar
• TokunagaEKimuraYMashinoKActivation of PI3K/Akt signaling and hormone resistance in breast cancerBreast Cancer200613213714416755107
   PubMedGoogle Scholar
• EndDWSmetsGToddAVCharacterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitroCancer Research200161113113711196150
   PubMed Web of Science ®Google Scholar
• DalencFDoisneau-SixouSFAllalBCTipifarnib plus tamoxifen in tamoxifen-resistant metastatic breast cancer: a negative phase II and screening of potential therapeutic markers by proteomic analysisClin Cancer Res20101641264127120145184
   PubMed Web of Science ®Google Scholar
• LiTGuoMGradisharWA phase II trial of capecitabine in combination with the farnesyltransferase inhibitor tipifarnib in patients with anthracycline-treated and taxane-resistant metastatic breast cancer: an Eastern Cooperative Oncology Group Study (E1103)Breast Cancer Res Treat2012134134535222547107
   PubMed Web of Science ®Google Scholar
• LiTChristosPJSparanoJAPhase II trial of the farnesyltransferase inhibitor tipifarnib plus fulvestrant in hormone receptor-positive metastatic breast cancer: New York Cancer Consortium Trial P6205Ann Oncol200920464264719153124
   PubMed Web of Science ®Google Scholar
• JohnstonSSemiglazovVManikhasGA phase II, randomized, blinded study of the farnesyltransferase inhibitor tipifarnib combined with letrozole in the treatment of advanced breast cancer after antiestrogen therapyBreast Cancer Res Treat2008110232733517851757
   PubMed Web of Science ®Google Scholar
• GelmonKATischkowitzMMackayHOlaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised studyLancet Oncol201112985286121862407
   PubMed Web of Science ®Google Scholar
• TuttARobsonMGarberJEOral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trialLancet376973723524420609467
   PubMed Web of Science ®Google Scholar
• O’ShaughnessyJSchwartzbergLSDansoMAA randomized phase III study of iniparib (BSI-201) in combination with gemcitabine/carboplatin (G/C) in metastatic triple-negative breast cancer (TNBC)J Clin Oncol201129Suppl 15 abstr 1007
   Google Scholar
• RelfMLeJeuneSScottPAEExpression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor β-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesisCancer Res19975759639699041202
   PubMed Web of Science ®Google Scholar
• ShihTLindleyCBevacizumab: an angiogenesis inhibitor for the treatment of solid malignanciesClin Ther200628111779180217212999
   PubMed Web of Science ®Google Scholar
• MilesDWChanADirixLYPhase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast CancerJ Clin Oncol201028203239324720498403
   PubMed Web of Science ®Google Scholar
• MillerKDChapLIHolmesFARandomized Phase III Trial of Capecitabine Compared With Bevacizumab Plus Capecitabine in Patients With Previously Treated Metastatic Breast CancerJ Clin Oncol200523479279915681523
   PubMed Web of Science ®Google Scholar
• RobertNJDiérasVGlaspyJRIBBON-1: randomized, double-blind, placebo-controlled, phase iii trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2–negative, locally recurrent or metastatic breast cancerJ Clin Oncol201129101252126021383283
   PubMed Web of Science ®Google Scholar
• MillerKWangMGralowJPaclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancerN Engl J Med2007357262666267618160686
   PubMed Web of Science ®Google Scholar
• BrufskyAHurvitzSAPerezEAFinal overall survival (OS) and safety analyses of RIBBON-2, a randomised phase III trial of bevacizumab (BEV) versus placebo (PL) combined with second line chemotherapy (CT) for HER2-negative-BEV-naive metastatic breast cancer (MBC)J Clin Oncol201230Suppl 27 abstr 100
   Web of Science ®Google Scholar
• CameronDBrownJDentRPrimary results of BEATRICE, a randomized phase III trial evaluating adjuvant bevacizumab-containing therapy in triple-negative breast cancerCancer Research20127224, Suppl 3 Available from: http://cancerres.aacrjournals.org/cgi/content/short/72/24_MeetingAbstracts/S6-5?rss=1Accessed May 20, 2013
   Google Scholar
• Moreno-AspitiaAMortonRFHillmanDWPhase II trial of sorafenib in patients with metastatic breast cancer previously exposed to anthracyclines or taxanes: North Central Cancer Treatment Group and Mayo Clinic Trial N0336J Clin Oncol2009271111519047293
   PubMed Web of Science ®Google Scholar
• BaselgaJSegallaJGMRochéHSorafenib in combination with capecitabine: an oral regimen for patients with HER2-negative locally advanced or metastatic breast cancerJ Clin Oncol201230131484149122412143
   PubMed Web of Science ®Google Scholar
• BarriosCHLiuMCLeeSCPhase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancerBreast Cancer Res Treat2010121112113120339913
   PubMed Web of Science ®Google Scholar
• CrownJDierasVStaroslawskaEPhase III trial of sunitinib (SU) in combination with capecitabine (C) versus C in previously treated advanced breast cancer (ABC)J Clin Oncol201028Suppl abstr 18
   Google Scholar
• BerghJBondarenkoIMLichinitserMRFirst-line treatment of advanced breast cancer with sunitinib in combination with docetaxel versus docetaxel alone: results of a prospective, randomized phase III studyJ Clin Oncol201230992192922331954
   PubMed Web of Science ®Google Scholar
• MillerKDTrigoJMWheelerCA multicenter phase II trial of ZD6474, a vascular endothelial growth factor receptor-2 and epidermal growth factor receptor tyrosine kinase inhibitor, in patients with previously treated metastatic breast cancerClin Cancer Res20051193369337615867237
   PubMed Web of Science ®Google Scholar
• BoérKLángILlombart-CussacAVandetanib with docetaxel as second-line treatment for advanced breast cancer: a double-blind, placebo-controlled, randomized phase II studyInvest New Drugs201230268168720830502
   PubMed Web of Science ®Google Scholar
• WoodJMBoldGBuchdungerEPTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administrationCancer Res20006082178218910786682
   PubMed Web of Science ®Google Scholar
• US National Institutes of HealthPTK787 + Trastuzumab for HER2 Overexpressing Metastatic Breast Cancer Available from: http://clinicaltrials.gov/ct2/show/results/NCT00216047Accessed June 23rd, 2013
   Google Scholar